All News

Integrating specialty pharmacists into neurology teams enhances patient care, medication management, and clinical outcomes for chronic conditions.

Innovative pain management strategies emerge as experts advocate for personalized, multifaceted approaches to chronic pain, likening treatment to a tailored cupcake.

Rilonacept offers a targeted approach to treating recurrent pericarditis by blocking IL-1 inflammatory pathways.

New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.

Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.

Subcutaneous immunoglobulin was found to elicit fewer viral infections compared with other routes of immunoglobulin replacement therapy, including intravenous immunoglobulin.

The investigators suggested that blocking VPS72’s interactions can be a foundation for future therapeutic interventions.

Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.

Never taking a break does more harm than good.

Juan Ovalles, MD, PhD, discusses how high placebo response rates driven by background therapy complicate lupus drug trials, and outlines evolving strategies in trial design, clinical practice, and pharmacist-led care to ensure investigational biologics are fairly evaluated and appropriately used in systemic lupus erythematosus.

Pharmacists navigate reimbursement challenges while advocating for legislative support and innovative models to enhance patient care and financial sustainability.

Compared with standard of care, camizestrant in combination with a CDK4/6 inhibitor shows promise in enhancing progression-free survival (PFS) for patients with advanced breast cancer.

New products are poised to aid pharmacists in proper counting of inventory to prevent medication errors.

Vadadustat and darbepoetin alfa show similar safety and efficacy in treating CKD-related anemia, with regional differences impacting cardiovascular risks.

New research highlights vitamin D's potential to slow telomere shortening, suggesting it may combat aging and promote cellular health.

Implementation of the Plan-Do-Study-Act cycle in health system retail pharmacies significantly increased uptake of 20-valent pneumococcal conjugate vaccine among eligible adults.

Vincent Chung, MD, discusses key findings from the NAPOLI-3 trial and offers guidance for pharmacists on managing toxicities, adjusting dosing, and supporting patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma.

About 10% of patients report a penicillin allergy, but only around 1% are truly allergic. Recommending penicillin allergy testing can help patients determine whether they have a true allergy.

CDC urges all US travelers to get vaccinated for measles, mumps, and rubella (MMR) amid rising measles cases, emphasizing prevention as key to combating outbreaks.

Although women might benefit from fattier breakfasts, men could respond best to carbohydrates.

Subcutaneous immunoglobulin (SCIg) is a hopeful alternative to intravenous immunoglobulin in patients with inflammatory myositis due to a lack of adverse effects and fewer financial constraints.

Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.

New findings show LYR-210's potential to significantly alleviate chronic rhinosinusitis symptoms, offering hope for patients with nasal inflammation and polyps.

Results from the NeoADAURA trial demonstrate the sustained efficacy of osimertinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small-cell lung cancer (NSCLC).

New treatments for metabolic dysfunction-associated steatohepatitis (MASH)–related cirrhosis address unique challenges in drug development.

Ibrutinib plus venetoclax shows promising long-term survival rates, including those who are considered high risk.

Infectious Disease Society of America guidance defines difficult-to-treat resistant Pseudomonas aeruginosa as resistance to all first-line agents.